TITLE

Alzheimer's patients now have a topical option

PUB. DATE
July 2007
SOURCE
Drug Topics;7/23/2007, Vol. 151 Issue 14, p6
SOURCE TYPE
Trade Publication
DOC. TYPE
Product Review
ABSTRACT
The article evaluates Novartis Pharmaceuticals Corp.'s Exelon® Patch Rivastigmine transdermal system for the treatment of Alzheimer's disease.
ACCESSION #
26131607

 

Related Articles

  • FDA approves new quadrivalent meningococcal vaccine. Thompson, Cheryl A. // American Journal of Health-System Pharmacy;4/1/2010, Vol. 67 Issue 7, p504 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) to the quadrivalent meningococcal vaccine Menveo of Novartis Pharmaceutical Corp. as announced by the company on February 22, 2010 which allows its marketing of the vaccine.

  • IBS-Drug Treatment Pulled, CV Side Effects. Elliott, William T. // Critical Care Alert;May2007 Pharmacology Watch, p1 

    The article reports on the removal from the market of tegaserod, a drug for irritable bowel syndrome from Novartis Pharmaceutical, by the U.S. Food and Drug Administration (FDA) after recent findings associated the drug with increased risk of cardiovascular (CV) events.

  • Mo. Plains facility sold to Novartis in $43M deal. Kaltwasser, Jared // njbiz;12/24/2012, p2 

    The article announces the sale of biotechnology company Dendreon Corp.'s immunotherapy manufacturing facility in Morris Plains, New Jersey, to Novartis Pharmaceuticals Corp. for 43 million U.S. dollars in cash.

  • GILENYA.  // MPR - Pharmacist's Edition;Winter2010/2011, Vol. 4 Issue 4, pA.5 

    The article evaluates Gilenya from Novartis Pharmaceuticals Corp.

  • Direct-to-consumer advertising touts free samples. Rose, Joan R. // Medical Economics;12/3/2001, Vol. 78 Issue 23, p14 

    Focuses on vouchers for free drug samples offered through the Internet by Novartis Pharmaceuticals and MedManage Systems. Benefits from the vouchers.

  • FDA approves new drug for children, adults with epilepsy.  // Hudson Valley Business Journal;01/31/2000, Vol. 10 Issue 25, p18 

    Reports that Novartis Pharmaceuticals Corp.'s Trileptal oxcarbazepine tablets has been approved by the United States Food and Drug Administration for marketing. Use of the drug for treating partial seizures in adults and children.

  • Afinitor Targets a Form Of Pancreatic Cancer.  // Chain Drug Review;6/6/2011, Vol. 33 Issue 10, p42 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) to Novartis Pharmaceuticals Corp.'s Afinitor drugs which can used for the treatment of progressive neuroendocrine tumors (NET) in East Hanover, New Jersey.

  • Labelling for tegaserod updated to reflect ischaemic colitis risk.  // Reactions Weekly;5/8/2004, Issue 1000, p3 

    Reports on the changes done by U.S.-based Novartis Pharmaceuticals Corporation to the product label of the drug Zelnorm. Therapeutic use for the drug; Potential side effects of the drug; Update in the precautionary information contained in the package insert for the drug.

  • ASM 981 cream moves for NDA.  // Dermatology Times;Jan2001, Vol. 22 Issue 1, p3 

    Reports the application of ASM 981 for drug certification to the Food and Drug Administration by Novartis Pharmaceutical Corp. in East Hanover, New Jersey.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics